What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.

AbbVie demonstrated successful pipeline diversification in Q3, with 9.1% revenue growth to $15.8 billion, propelled by strong Skyrizi and Rinvoq sales offsetting Humira's post-exclusivity decline, alongside a 5.5% dividend increase. UnitedHealth Group, despite a 34% YTD stock drop, reported a 12% Q3 revenue increase to $113.2 billion and raised its full-year adjusted EPS guidance, indicating a potential operational rebound. Concurrently, CVS Health posted robust Q3 results, with revenue up 7.8% to $102.8 billion and adjusted operating income surging 35%, contributing to its 74% YTD stock appreciation and attractive 3.4% dividend yield, highlighting strong momentum across its integrated healthcare model.

Analysis

AbbVie reported strong Q3 revenue growth of 9.1% to $15.8 billion, primarily fueled by significant increases in Skyrizi (up 46.8%) and Rinvoq (up 35.3%) sales. This performance effectively mitigated the anticipated 55.4% decline in Humira revenue following its exclusivity loss, underscoring successful pipeline diversification. The company also announced a 5.5% dividend increase to $1.73 per share, reflecting confidence in future cash flows.

CVS Health demonstrated robust Q3 results, with revenue rising 7.8% to $102.8 billion and adjusted operating income surging 35% to $3.45 billion. This strong operational performance across its integrated healthcare segments contributed to a remarkable 74% year-to-date stock appreciation and a compelling 3.4% dividend yield. The company issued full-year guidance of at least $397 billion in revenue and adjusted EPS of $6.55 to $6.65.

UnitedHealth Group, despite a 34% year-to-date stock decline and a $6.5 billion misjudgment in 2025 medical claims, posted a 12% Q3 revenue increase to $113.2 billion. The company raised its full-year adjusted EPS guidance to $16.25 and is implementing strategic changes to Medicare Advantage benefits and pricing for 2026 and 2027, indicating proactive management of its challenges. All three healthcare companies offer dividend yields above the sector average of 1.8%.

Key Decisions for Investors

• Consider AbbVie for its successful product diversification and consistent dividend growth, despite Humira's patent expiry.
• Evaluate CVS Health for its strong integrated healthcare model and significant Q3 earnings momentum, coupled with an attractive dividend yield.
• Monitor UnitedHealth Group's strategic adjustments for 2026/2027 and potential operational rebound, as its current valuation may offer a long-term entry point.